These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 30255633)

  • 1. Anaplastic pleomorphic xanthoastrocytoma with leptomeningeal dissemination responsive to BRAF inhibition and bevacizumab.
    Thomas AA; Tucker SM; Nelson CJ; Nickerson JP; Durham SR; Homans AC
    Pediatr Blood Cancer; 2019 Jan; 66(1):e27465. PubMed ID: 30255633
    [No Abstract]   [Full Text] [Related]  

  • 2. Dabrafenib and trametinib in BRAFV600E mutated glioma.
    Brown NF; Carter T; Kitchen N; Mulholland P
    CNS Oncol; 2017 Oct; 6(4):291-296. PubMed ID: 28984141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained Response to Targeted Therapy in a Patient With Disseminated Anaplastic Pleomorphic Xanthoastrocytoma.
    Amayiri N; Swaidan M; Al-Hussaini M; Halalsheh H; Al-Nassan A; Musharbash A; Tabori U; Hawkins C; Bouffet E
    J Pediatr Hematol Oncol; 2018 Aug; 40(6):478-482. PubMed ID: 29200156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response to the BRAF/MEK inhibitors dabrafenib/trametinib in an adolescent with a BRAF V600E mutated anaplastic ganglioglioma intolerant to vemurafenib.
    Marks AM; Bindra RS; DiLuna ML; Huttner A; Jairam V; Kahle KT; Kieran MW
    Pediatr Blood Cancer; 2018 May; 65(5):e26969. PubMed ID: 29380516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF exon 11 mutant melanoma and sensitivity to BRAF/MEK inhibition: Two case reports.
    Melin A; Routier E; Tissot H; Rouleau E; Robert C
    Eur J Cancer; 2019 Nov; 121():109-112. PubMed ID: 31569065
    [No Abstract]   [Full Text] [Related]  

  • 6. Primary CNS Metastatic BRAF-mutated Lung Adenocarcinoma With Complete Intracranial Response to BRAF/MEK Inhibition.
    Tsakonas G; Grozman V; Ekman S
    Clin Lung Cancer; 2020 Nov; 21(6):e544-e546. PubMed ID: 32522509
    [No Abstract]   [Full Text] [Related]  

  • 7. Rapid evolution of combination therapy in melanoma.
    Curti BD
    N Engl J Med; 2014 Nov; 371(20):1929-30. PubMed ID: 25390744
    [No Abstract]   [Full Text] [Related]  

  • 8. Rapid regression of metastatic brain tumours in a melanoma patient after dabrafenib/trametinib therapy.
    Komori T; Otsuka A; Kusuba N; Taniguchi K; Endo Y; Honda T; Kabashima K
    Eur J Dermatol; 2017 Oct; 27(5):548-549. PubMed ID: 29084644
    [No Abstract]   [Full Text] [Related]  

  • 9. Using personalized medicine in gliomas: a genomic approach to diagnosis and overcoming treatment resistance in a case with pleomorphic xanthoastrocytoma.
    Piña Y; Fusco MJ; Macaulay RJ; Walko CM; Peguero E; Evernden BR; Smalley KS; Forsyth P
    J Neurol; 2020 Mar; 267(3):783-790. PubMed ID: 31748891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disseminated anaplastic pleomorphic xanthoastrocytoma with posttreatment fat necrosis during combined BRAF and MEK inhibitors therapy.
    Phadnis SS; Chen L; Wang WL; Migden MR; Zaky W
    Pediatr Blood Cancer; 2019 Dec; 66(12):e27974. PubMed ID: 31502413
    [No Abstract]   [Full Text] [Related]  

  • 11. Dabrafenib in BRAFV600-mutated anaplastic pleomorphic xanthoastrocytoma.
    Brown NF; Carter T; Mulholland P
    CNS Oncol; 2017 Jan; 6(1):5-9. PubMed ID: 27781490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
    Menzies AM; Long GV
    Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dosing of BRAK and MEK Inhibitors in Melanoma: No Point in Taking a Break.
    Lee JH; Carlino MS; Rizos H
    Cancer Cell; 2020 Dec; 38(6):779-781. PubMed ID: 33321086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fatherhood during dabrafenib and trametinib therapy for metastatic melanoma.
    Cocorocchio E; Pala L; Battaglia A; Gandini S; Peccatori FA; Ferrucci PF
    Acta Oncol; 2018 Aug; 57(8):1131-1133. PubMed ID: 29526130
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical and Radiographic Response of Leptomeningeal and Brain Metastases to Encorafenib and Binimetinib in a Patient With BRAF V600E-Mutated Lung Adenocarcinoma.
    McLoughlin EM; Fadul CE; Patel SH; Hall RD; Gentzler RD
    J Thorac Oncol; 2019 Dec; 14(12):e269-e271. PubMed ID: 31757377
    [No Abstract]   [Full Text] [Related]  

  • 16. Challenges of targeting
    Smith-Cohn M; Davidson C; Colman H; Cohen AL
    CNS Oncol; 2019 Dec; 8(4):CNS48. PubMed ID: 31818130
    [No Abstract]   [Full Text] [Related]  

  • 17. [The Role of BRAF/MEK Inhibition in Metastatic Malignant Melanoma - a Case Study].
    Kopecký J; Kubeček O
    Klin Onkol; 2016; 29(2):133-8. PubMed ID: 27081804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brugada syndrome induced by BRAF and MEK inhibitors in a melanoma patient.
    Nardin C; Colas M; Badoz M; Roche-Kubler B; Meneveau N; Puzenat E; Aubin F
    Eur Heart J; 2017 Jul; 38(27):2151. PubMed ID: 28329154
    [No Abstract]   [Full Text] [Related]  

  • 19. Successful re-challenge with anti-BRAF and anti-MEK in a patient with symptomatic melanoma flare.
    Ibrahim T; Routier E; Weill A; Baz M; Robert C
    Eur J Cancer; 2017 Sep; 82():25-26. PubMed ID: 28646770
    [No Abstract]   [Full Text] [Related]  

  • 20. Histiocytoid Sweet's syndrome during combined therapy with BRAF and MEK inhibitors for metastatic melanoma.
    Morgado-Carrasco D; Moreno-Rivera N; Fustà-Novell X; García-Herrera A; Carrera C; Puig S
    Melanoma Res; 2018 Jun; 28(3):256-257. PubMed ID: 29683894
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.